loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
Open ICICI 3-in-1 Account

Hester Biosciences Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Hester Biosciences Ltd. 15 May 2026 18:38 PM
Result PDF

Q4FY26 & FY26 Result Announced for Hester Biosciences Ltd.

Pharmaceuticals company Hester Biosciences announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Revenue from Operations for Q4FY26 was reported at Rs 1,001.10 million, reflecting a 22.20% YoY increase from Rs 819.25 million in Q4FY25, and a 29.32% QoQ growth from Rs 774.15 million in Q3FY26.
  • Total Income for Q4FY26 stood at Rs 970.82 million, up 29.49% YoY from Rs 749.75 million in Q4FY25, and an increase of 24.33% QoQ from Rs 780.84 million in Q3FY26.
  • EBITDA for Q4FY26 stood at Rs 360.97 million, a robust growth of 167% YoY compared to Rs 135.41 million in Q4FY25.
  • Profit After Tax (PAT) for Q4FY26 soared by 973.72% YoY to Rs 165.46 million from Rs 15.41 million in Q4FY25, and climbed 77.72% QoQ from Rs 93.10 million in Q3FY26.
  • For the full year FY26, Revenue from Operations was Rs 3,325.99 million, growing by 6.91% YoY from Rs 3,111.02 million in FY25.
  • Total Income for FY26 reached Rs 3,422.83 million, up 8.65% YoY from Rs 3,150.26 million in FY25.
  • Profit After Tax (PAT) for FY26 demonstrated a strong 99.42% YoY growth, closing at Rs 574.84 million compared to Rs 288.26 million in FY25.

Standalone Financial Highlights:

  • Revenue from Operations for Q4FY26 stood at Rs 937.13 million, registering a growth of 22.23% YoY compared to Rs 766.72 million in Q4FY25, and an increase of 33.20% QoQ from Rs 703.54 million in Q3FY26.
  • Total Income for Q4FY26 was Rs 978.92 million, up 25.93% YoY from Rs 777.30 million in Q4FY25, and up 37.12% QoQ from Rs 713.89 million in Q3FY26.
  • EBITDA for Q4FY26 witnessed significant growth, reaching Rs 426.40 million, an increase of 189% YoY from Rs 147.60 million in Q4FY25.
  • Profit After Tax (PAT) for Q4FY26 surged by 173.83% YoY to Rs 263.84 million against Rs 96.35 million in Q4FY25, and grew by 147.30% QoQ from Rs 106.69 million in Q3FY26.
  • For the full year FY26, Revenue from Operations was Rs 2,921.36 million, a growth of 1.98% YoY from Rs 2,864.66 million in FY25.
  • Total Income for FY26 stood at Rs 2,997.71 million, an increase of 2.93% YoY from Rs 2,912.30 million in FY25.
  • Profit After Tax (PAT) for FY26 jumped by 63.62% YoY to Rs 521.00 million, up from Rs 318.42 million in FY25.

Business & Segment Highlights:

  • Poultry Healthcare Division: Recorded strong growth during Q4FY26 with revenues of Rs 650.20 million, up 41% YoY from Rs 460.85 million in Q4FY25. For FY26, revenue stood at Rs 2,060.79 million, up 24% YoY from Rs 1,664.39 million in FY25. Growth was supported by improved market penetration, expanded placements, and sustained demand for vaccines.
  • Animal Healthcare Division: Q4FY26 revenue stood at Rs 286.41 million, declining 6% YoY from Rs 305.37 million in Q4FY25. FY26 revenue was Rs 818.32 million, down 32% YoY from Rs 1,198.83 million in FY25. The division continued to be impacted by delays in government immunisation programmes and uneven demand across certain commercial markets.
  • Dividend: The Board of Directors recommended a dividend of Rs 11 per equity share of Rs 10 each (110%) for the financial year 2025-26.
  • Divestment: The Board approved the divestment of a 43.81% equity shareholding (out of its 54.81% stake) in its subsidiary, Texas Lifescience Private Limited (TLPL), by transferring 2,163,377 equity shares at Rs 42.34 per share. Consequently, TLPL ceased to be a subsidiary from 27 March 2026.
  • Operational Updates: During the quarter, the company capitalised its BSL 3 facility as part of its ongoing capacity expansion and infrastructure strengthening initiatives. It also received marketing and manufacturing licences for its H9N2 Avian Influenza vaccine, strengthening its poultry vaccine portfolio.
  • Profitability Drivers: Gross profit margins improved to 78% in Q4FY26 and 72% for the full year FY26, supported by a favourable product mix and continued operational discipline. EBITDA and PAT growth were driven by a stronger contribution from the Poultry Healthcare Division and continued cost optimisation initiatives.
  • Overseas Operations: Overseas markets witnessed mixed conditions, though the company strengthened its presence across selected African and export markets. The company also continued its participation in the GALVmed-led VITAL 2 programme focused on vaccine awareness and adoption in Africa.
  • Re-appointment: The Board approved the re-appointment of Ms. Priya Gandhi as Executive Director for a period of 3 years, effective from 28 October 2026.

Result PDF

Result PDF

Pharmaceuticals company Hester Biosciences announced Q3FY26 results

  • Revenue: Rs 774.15 million against Rs 632.18 million during Q3FY25, change 22%.
  • EBITDA: Rs 197.77 million against Rs 138.45 million during Q3FY25, change 43%.
  • EBITDA Margin: 26% for Q3FY26.
  • PAT: Rs 93.1 million against Rs 114.08 million during Q3FY25, change -18%.
  • PAT Margin: 12% for Q3FY26.
  • EPS: 10.94 for Q3FY26.
  • The Poultry Healthcare Division delivered 32% growth in Q3 FY26 and 17% growth in 9M FY26, driven by deeper market penetration, improved placements and sustained demand for our vaccines.
  • The Animal Healthcare Division recorded a 38% decline in Q3 FY26 and a 40% decline in 9M FY26, primarily due to delays in government-led immunisation programmes in the ruminant segment, particularly PPR and Goat Pox (for immunising against the Lumpy Skin Disease).

Result PDF

Pharmaceuticals company Hester Biosciences announced Q2FY26 results

  • Revenue from operations: Rs 709.69 million against Rs 836.92 million during Q2FY25, change -15%.
  • EBITDA: Rs 235.97 million against Rs 219.55 million during Q2FY25, change 7%.
  • EBITDA Margin: 33% for Q2FY26.
  • PAT: Rs 143.31 million against Rs 83.91 million during Q2FY25, change 71%.
  • PAT Margin: 20% for Q2FY26.
  • EPS: Rs 16.85 for Q2FY26.

Result PDF

Pharmaceuticals company Hester Biosciences announced Q1FY26 results

  • Revenue from operations: Rs 841.05 million compared to Rs 822.67 million during Q1FY25, change 2%.
  • EBITDA: Rs 261.79 million compared to Rs 197.35 million during Q1FY25, change 33%.
  • EBITDA Margin: 31% for Q1FY26.
  • PAT: Rs 172.96 million compared to Rs 74.86 million during Q1FY25, change 131%.
  • EPS: Rs 20.33 for Q1FY26.
  • Animal Healthcare Division: In Q1FY26, the division recorded a 33% decline in sales, primarily due to timing delays in key government Immunisation programmes for PPR and Lumpy Skin Disease, in which Hester’s PPR and Goat Pox vaccines respectively, are widely used, have got delayed.
  • Poultry Healthcare Division: The Poultry Healthcare Division recorded a 2% growth in Q1FY26, led by robust demand for key vaccines, particularly for Newcastle Disease and Marek’s Disease.

Result PDF

Pharmaceuticals company Hester Biosciences announced Q4FY25 results

  • Revenue from operations: Rs 819.25 million compared to Rs 792.55 million during Q4FY24, change 3%.
  • Gross Profit Margin: Rs 611.83 million compared to Rs 577.16 million during Q4FY24, change 6%.
  • EBITDA: Rs 135.41 million compared to Rs 205.48 million during Q4FY24, change -34%.
  • EBITDA margin: 17% for Q4FY25.
  • PAT: Rs 15.41 million compared to Rs 63.95 million during Q4FY24, change -76%.
  • PAT margin: 2% for Q4FY25.

Result PDF

Pharmaceuticals company Hester Biosciences announced Q3FY25 results

  • Divisional Product Sales: Rs 632.18 million, down 6% YoY from Rs 669.83 million
  • Revenue from Operations: Rs 632.18 million, down 6% YoY from Rs 669.83 million
    • Hester Nepal: Rs 8.09 million, up 2% YoY from Rs 7.91 million
    • Hester Africa: Rs 8.05 million, up 11% YoY from Rs 7.26 million
  • Gross Profit Margin: Rs 435.93 million, down 6% YoY from Rs 463.44 million
  • EBITDA: Rs 138.45 million, up 12% YoY from Rs 123.53 million
  • EBITDA %: 22%, up 4% YoY from 18%
  • PAT: Rs 114.08 million, up 184% YoY from Rs 40.20 million
  • PAT %: 18%, up 12% YoY from 6%
  • EPS: Rs 13.41, up 184% YoY from 4.73

Result PDF

Pharmaceuticals company Hester Biosciences announced Q2FY25 results

  • Revenue from operations: Rs 836.92, compared to Q2FY24 Rs 704.55 change 19%.
  • Consolidated EBITDA: Rs 219.55 million change 15%
  • Q2FY25 Consolidated Divisional Product sales up by 21% & Profit up by 108%.
  • Hester Nepal achieved net profit of Rs 0.29 million in Q2FY25, reversing from a loss of Rs 7.05 million in Q2FY24. The subsidiary fulfilled export orders from government tenders and met domestic vaccine demand, showcasing its growth potential. Hester Nepal remains debt-free with strong cash flows from the quarter.
  • Hester Africa reduced its net loss to Rs 23.67 million in Q2FY25, down from net loss of Rs 49.17 million in Q2FY24. Hester Africa is actively participating in international tenders and meeting trade demands across various African countries, with increasing awareness and demand for vaccines.

Result PDF

Pharmaceuticals company Hester Biosciences announced Q1FY25 results:

  • Q1FY25 Standalone Divisional Product sales up by 37% & Profit up by 30%
  • Q1FY25 Consolidated Divisional Product sales up by 35% & Profit up by 9%
  • The divisional performance has demonstrated growth in the current quarter compared to Q1FY24, with sales increasing by 37%.
  • The overall sales show a decrease of 9% QoQ, primarily attributed to the one-time sales of other pharmaceutical products in Q1FY24.
  • Hester focused on higher-margin products and solutions in Q1FY25, leading to a significant rise in gross profit margin from 57% to 69%.
  • Increased revenue from divisional product sales allowed for better absorption of fixed costs, resulting in a 5% improvement in EBITDA%.
  • Overall absolute PAT increased by 30% and PAT% ratio increased by 3%, reflecting improved operational efficiency.

Result PDF

Pharmaceuticals company Hester Biosciences announced Q4FY24 & FY24 results:

Financial Highlights:

  • Hester Biosciences reported an increase in standalone revenue by 20% and consolidated revenue by 18% in Q4FY24 compared to the previous year.
  • The audited financial results for Q4 & FY24 show the company's resilience with a recommendation for a dividend of 6 per equity share of Rs 10 each (60%) for FY24, awaiting shareholder approval.
  • The company has reduced its borrowing by 19% and increased cash generated from operations by 28% during the year.
  • Overall gross profit margin in Q4FY24 increased by 1% compared to Q4FY23, primarily due to the increase in the proportion of vaccines from 60% to 75% in Q4FY24.
  • In Q4FY24, EBITDA increased by 14% in alignment with a growth in sales, resulting in a 19% increase in PAT for the quarter.
  • The total borrowings of the Company has reduced by Rs 307.58 million (19%) during the year.
  • The cash generated from operations has increased by Rs 94.50 million (28%) during the year

Animal Healthcare Division:

  • The Animal Healthcare division saw a growth of 89% in Q4FY24, driven by sales of Goat Pox vaccine and vaccines for a government immunisation program.
  • Despite regulatory challenges, the Animal Healthcare division has demonstrated the ability to recover and sustain growth.

Poultry Healthcare Division:

  • The Poultry Healthcare division achieved a notable growth of 22% in Q4FY24, with a consistent upward trend throughout the year.
  • Strategic introductions of new products and leveraging market opportunities have been instrumental in the division's sales performance.

Petcare Division:

  • In Q4FY24, the Petcare division saw a minor decrease in sales from the previous quarter but reported a notable annual growth of 49%.
  • The Petcare division's focus on building a strong foundation and delivering high-quality products is reflected in its substantial growth.

Result PDF

Pharmaceuticals company Hester Biosciences announced Q2FY24 & H1FY24 results:

1. Financial Performance:

  • Q2FY24:
    • Revenue from Operations: Rs 704.55 crore, down 4% YoY
    • EBITDA: Rs 132.12 crore, up 4% YoY
    • Profit after Tax (excl. OCI): Rs 40.41 crore, down 39% YoY
    • Earnings Per Share (EPS): Rs 4.75, down 39% YoY
  • H1FY24:
    • Revenue from Operations: Rs 1,583.08 crore, up 28% YoY
    • EBITDA: Rs 275.75 crore, up 37% YoY
    • Profit after Tax (excl. OCI): Rs 107.51 crore, up 6% YoY
    • Earnings Per Share (EPS): Rs 12.64, up 6% YoY

2. Division Performance:
-  Animal Healthcare division experienced a 16% decline in sales in Q2FY24 due to uneven sales of the Goat Pox Vaccine.
- Poultry Healthcare division saw a 4% decrease in overall sales in Q2FY24, with a growth in domestic vaccine sales, but a reduction in export sales.
- Petcare division achieved impressive performance, growing 98% in Q2FY24.

3. Subsidiary Performance:
- Hester Nepal had a turnover of Rs 7.28 million in Q2FY24, primarily from domestic sales of vaccines, with an overall net loss of Rs 7.05 million.
- Hester Africa continued export sales but faced an overall loss of Rs 49.17 million due to foreign exchange fluctuations.
- Hester's share of profit in the joint venture entity, Thrishool Exim Limited (Tanzania), increased by 9.86 million in Q2FY24.

 

 

Result PDF

Trending News

BEL bags ₹608 cr orders from Defence Ministry for communication and electronic systems

BEL has secured additional orders worth ₹608 crore from the Ministry of Defence. 

Published on 26-May-2026 09:10

Amara Raja Q4 PAT spikes 93% to ₹322 cr on insurance gain; FY26 sales up 9% to ₹13,549 cr

On standalone basis, net sales for the quarter came in at ₹ 3,460 crore, up 16% YoY. EBITDA in Q4FY26 came in at ₹ 377 crore with corresponding EBITDA margins at 10.9%, down ~30 bps QoQ. 

Published on 26-May-2026 09:09

Ashok Leyland bags order for 715 vehicles from VRL Logistics; 300 units already delivered

In a press release, Ashok Leyland announced that it has secured an order for 715 vehicles from VRL Logistics, further strengthening their decades-long partnership. 

Published on 26-May-2026 09:08

Cyient Semiconductors raises $30m led by Edelweiss funds at a $500m valuation

Cyient Limited announced that its subsidiary, Cyient Semiconductors, has secured a strategic financing transaction led by Edelweiss-managed funds at a post-money equity valuation of ~ US$500 million (~ ₹4,600 crore). 

Published on 26-May-2026 09:07

Sudarshan Chemicals Q4 revenue surges 33% QoQ to ₹2,790 cr; net profit hits ₹82.5 cr

Sudarshan Chemicals in Q4FY26 reported revenues of ₹2,790 crore, up 33% QoQ The pigment business (96% of revenues) reported revenues of ₹2,689 crore, up 31% QoQ. 

Published on 26-May-2026 09:06

Brigade Enterprises signs JDA for ₹850-crore residential project in Kompally, Hyderabad

Brigade Enterprises has secured a Joint Development Agreement (JDA) to develop a project spread across 5.6 acres having estimated gross development value (GDV) of ₹850 crore at Kompally, Hyderabad.

Published on 26-May-2026 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app